Skip to main content
Equibles

Glen Santangelo

Analyst

Barclays

Analyst

Guggenheim

Analyst

Jefferies

Equibles does not estimate personal net worth.

About Glen Santangelo

Glen Santangelo is recorded as Analyst at Barclays, Analyst at Guggenheim and Analyst at Jefferies. Glen Santangelo has spoken on 33 earnings calls and 9 other investor events across 20 companies, most recently for Alvotech on August 20, 2026. Those appearances were for Viatris Inc (VTRS), Teva Pharmaceutical Industries Ltd (TEVA), Cencora, Inc. (COR), Henry Schein Inc (HSIC), Amneal Pharmaceuticals, Inc. (AMRX) and 15 other companies. The companies whose calls Glen Santangelo spoke on are classified in the Healthcare sector.

Glen Santangelo on recent calls

“Hey, I just wanted to ask a quick question about the guidance, and then I have a couple of follow-ups.”
Analyst — Barclays, Q2 2026 Earnings Call ·
“In the past, you told us that eucalyptus was currently generating about a break-even margin. Is that still the case? And any help there you can give us? And then my follow-up is really around longer-term margins.”
Analyst — Barclays, Hims & Hers Second Quarter 2026 Earnings Call ·
“Oh, yeah, thanks for taking my question. Hey, Nikhil, at the beginning of the year, you called out all these prior authorization and re-verification issues that would impact 1Q. But then on May 8th, when you reported 1Q, you said that this was kind of behind the company.”
Analyst — Barclays, ANI Pharmaceuticals, Inc. Second Quarter 2026 Earnings Call ·
“You specifically called out Zanrelli and Quattro as being the biggest contributors to growth. And my question is really on the pricing environment around those drugs.”
Analyst — Barclays, ELAN Q2 2026 Earnings Call ·

Affiliation history

  • Barclays

    Analyst

    Source not stated

    Current

  • Guggenheim

    Analyst

    Source not stated

    Current

  • Jefferies

    Analyst

    Source not stated

    Current

Company network

Recent activity

Show 30 earlier activities